Perrigo Company plc Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number
Perrigo Company plc (PRGO) had Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number of 951.00 thousand shares as of 2023-12-31, per its 10-K filed 2024-02-27.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber · last filed 2024-02-27
- 2023-12-31: Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number 951.00K shares.
- 2022-12-31: Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number 1.13M shares.
- 2021-12-31: Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number 1.25M shares.
- 2020-12-31: Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number 1.14M shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number |
|---|---|
| 2023-12-31 | 951.00K shares 10-K · filed 2024-02-27 |
| 2022-12-31 | 1.13M shares 10-K · filed 2023-02-28 |
| 2021-12-31 | 1.25M shares 10-K · filed 2022-03-01 |
| 2020-12-31 | 1.14M shares 10-K · filed 2021-03-01 |
| 2019-12-31 | 1.01M shares 10-K · filed 2020-02-27 |
| 2018-12-31 | 764.00K shares 10-K · filed 2019-02-27 |
| 2017-12-31 | 519.00K shares 10-K · filed 2018-03-01 |
| 2016-12-31 | 473.00K shares 10-K · filed 2017-05-22 |
| 2015-12-31 | 614.00K shares 10-KT · filed 2016-02-25 |
| 2015-06-27 | 515.00K shares 10-K · filed 2015-08-13 |
| 2014-06-28 | 491.00K shares 10-K · filed 2014-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |